CDC42EP3 promotes colorectal cancer through regulating cell proliferation, cell apoptosis and cell migration

Qiang Feng, Dongkui Xu, Mingyao Zhou, Zijian Wu, Zhiyuan Wu, Zheng Wang, Jianjun Bi, Wei PeiCancer 2021 · DOI

TL;DR

This study identifies CDC42EP3 as a key promoter of colorectal cancer (CRC) progression. By knocking down CDC42EP3 in CRC cells, researchers found it significantly inhibited proliferation, colony formation, and migration, while simultaneously promoting apoptosis. These findings highlight CDC42EP3 as a promising therapeutic target for CRC.

What Problem Does This Paper Address?

Colorectal cancer (CRC) remains a major global health challenge, characterized by high incidence and mortality rates. While advancements in targeted therapies and chemotherapy have improved outcomes, the 5-year survival rate for advanced cases is still disappointingly low. This underscores the urgent need to identify novel therapeutic targets and deepen our understanding of the molecular mechanisms driving CRC progression. The role of CDC42EP3, a member of the Cdc42 effector protein family, in CRC has been largely unexplored, presenting a knowledge gap that this study aims to fill.

Methods

The researchers employed a multi-pronged approach to investigate CDC42EP3's role in CRC:

  • Cell Line Models: They constructed CDC42EP3 knockdown cell models using lentivirus-mediated shRNA in human colorectal cancer cell lines (HCT116 and RKO). This allowed for controlled manipulation of CDC42EP3 expression.
  • In Vitro Assays: A suite of standard cell-based assays were used to assess the functional impact of CDC42EP3 knockdown:
  • MTT Assay: To measure cell proliferation.
  • EdU Staining Assay: To quantify DNA synthesis and thus proliferation.
  • Colony Formation Assay: To assess the ability of cells to form colonies, indicative of sustained proliferation and survival.
  • Flow Cytometry (Annexin V-APC): To detect and quantify apoptotic cells.
  • Transwell Assay: To evaluate cell migration and invasion capabilities.
  • Immunohistochemistry (IHC): Used to examine CDC42EP3 expression levels in human colorectal cancer tissues and normal tissues, correlating expression with tumor grade and other clinical characteristics.
  • Western Blotting: To analyze the expression of key proteins involved in cell proliferation, apoptosis, and epithelial-mesenchymal transition (EMT).
  • Human Apoptosis Antibody Array: A high-throughput method to identify differentially expressed apoptosis-related proteins upon CDC42EP3 knockdown.
  • Xenograft Animal Model: Mouse models were used to validate the in vitro findings by assessing the impact of CDC42EP3 knockdown on tumor growth and metastasis in vivo.
  • Ki-67 Staining: Performed on xenograft tumors to assess cell proliferation rates in vivo.

Datasets

  • Human Colorectal Cancer Tissues: A microarray chip containing 97 colorectal cancer tissues and 75 normal tissues was used for immunohistochemistry analysis.
  • Colorectal Cancer Cell Lines: HCT116, RKO, SW480, and Caco2 cell lines were utilized for in vitro experiments.
  • Normal Human Colorectal Mucosal Cell Line: FHC was used as a control in western blotting.
  • Xenograft Model: Nude mice (BALB/c) were used to establish in vivo tumor models.

Key Insights and Ideas

  • CDC42EP3 as a CRC Oncogene: The study strongly suggests that CDC42EP3 is not just present but actively promotes CRC development and progression. Its upregulation in tumor tissues and correlation with advanced grades are compelling indicators.
  • Apoptosis Regulation is Key: A significant finding is that CDC42EP3 knockdown not only affects proliferation and migration but also profoundly impacts apoptosis. The identification of specific apoptosis-related proteins modulated by CDC42EP3 provides mechanistic insight.
  • EMT Connection: The observed changes in EMT markers (N-cadherin, E-cadherin, Vimentin, Snail) upon CDC42EP3 knockdown suggest that this protein plays a role in regulating the epithelial-mesenchymal transition, a critical process for tumor invasion and metastasis.
  • Signaling Pathway Involvement: The study hints at CDC42EP3's influence on crucial signaling pathways like Akt, CDK6, Cyclin D1, and PIK3CA, further elucidating its role in cell cycle control and proliferation.

Key Results

  • Upregulation in CRC: CDC42EP3 expression was significantly higher in colorectal cancer tissues compared to normal tissues, with increased expression correlating with advanced tumor grades.
  • Inhibition of Proliferation and Migration: Knockdown of CDC42EP3 in RKO and HCT116 cells led to a significant decrease in cell proliferation (measured by MTT and EdU assays) and colony formation. Cell migration was also substantially reduced, as evidenced by Transwell assays.
  • Promotion of Apoptosis: CDC42EP3 depletion resulted in a significant increase in apoptotic cell percentage. The apoptosis antibody array identified several key proteins (e.g., Bcl-2, cIAP-2, Survivin, TRAILR-4, XIAP) whose expression was altered, contributing to this effect.
  • EMT Suppression: Silencing CDC42EP3 led to the downregulation of EMT markers N-cadherin, Vimentin, and Snail, and upregulation of E-cadherin, indicating suppression of EMT.
  • Inhibition of Tumor Growth In Vivo: In mouse xenograft models, tumors formed by CDC42EP3-knockdown cells were significantly smaller and lighter, confirming the inhibitory effect on tumor growth. Ki-67 staining further supported reduced proliferation in these tumors.
  • Downregulation of Signaling Pathways: Knockdown of CDC42EP3 led to the downregulation of Akt, p-Akt, CDK6, Cyclin D1, and PIK3CA.

Limitations and Future Work

  • Mechanism of Action: While the study identifies key proteins and pathways affected by CDC42EP3 knockdown, the precise molecular mechanisms by which CDC42EP3 exerts its effects require further in-depth investigation.
  • Therapeutic Translation: The study demonstrates CDC42EP3's potential as a therapeutic target. Future work would involve developing and testing specific inhibitors or other therapeutic strategies targeting CDC42EP3 in preclinical and clinical settings.
  • Broader Patient Cohorts: While the IHC analysis used a decent number of samples, further validation across larger and more diverse patient cohorts could strengthen the findings.
  • In Vivo Complexity: The xenograft model provides valuable insights, but future studies could explore more complex in vivo models that better mimic the tumor microenvironment and metastatic processes.

Summary updated

Abstract

In conclusion, the role of CDC42EP3 in CRC was clarified and showed its potential as a target of innovative therapeutic approaches for CRC.
BibTeX
@inproceedings{feng2021cdc,
  author = {Qiang Feng and Dongkui Xu and Mingyao Zhou and Zijian Wu and Zhiyuan Wu and Zheng Wang and Jianjun Bi and Wei Pei},
  title = {{CDC42EP3 promotes colorectal cancer through regulating cell proliferation, cell apoptosis and cell migration}},
  booktitle = {Cancer},
  year = {2021},
  doi = {10.1186/s12935-021-01845-8},
}
Figure